2022
DOI: 10.3390/ijms23137088
|View full text |Cite
|
Sign up to set email alerts
|

Comparison of the Response to the CXCR4 Antagonist AMD3100 during the Development of Retinal Organoids Derived from ES Cells and Zebrafish Retina

Abstract: Retinal organoids generated from human embryonic stem cells or iPSCs recreate the key structural and functional features of mammalian retinal tissue in vitro. However, the differences in the development of retinal organoids and normal retina in vivo are not well defined. Thus, in the present study, we analyzed the development of retinal organoids and zebrafish retina after inhibition of CXCR4, a key role in neurogenesis and optic nerve development, with the antagonist AMD3100. Our data indicated that CXCR4 was… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 42 publications
0
1
0
Order By: Relevance
“…In 2008, it was approved by the US Food and Drug Administration (FDA) and combined with granulocyte colony stimulating factor (G-CSF) as a hematopoietic stem cell mobilization agent for autologous transplantation of patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM) [ 49 ]. During embryonic development, plerixafor treatment reduced the generation rate of retinal organs, damaged the differentiation of ganglion cells and induced morphological changes [ 50 ]. Since the use of plerixafor also had an inhibitory effect on palatal development in our preliminary experiment, it was difficult to reveal the teratogenicity of plerixafor on CP occurrence when 100 mg/kg RA was used in combination with plerixafor.…”
Section: Discussionmentioning
confidence: 99%
“…In 2008, it was approved by the US Food and Drug Administration (FDA) and combined with granulocyte colony stimulating factor (G-CSF) as a hematopoietic stem cell mobilization agent for autologous transplantation of patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM) [ 49 ]. During embryonic development, plerixafor treatment reduced the generation rate of retinal organs, damaged the differentiation of ganglion cells and induced morphological changes [ 50 ]. Since the use of plerixafor also had an inhibitory effect on palatal development in our preliminary experiment, it was difficult to reveal the teratogenicity of plerixafor on CP occurrence when 100 mg/kg RA was used in combination with plerixafor.…”
Section: Discussionmentioning
confidence: 99%